Manipulating non-coding RNA regulation to generate breakthrough medicines

bt_bb_section_bottom_section_coverage_image
https://www.leptonpharma.com/wp-content/uploads/2020/03/blue_triangle_01.png
https://www.leptonpharma.com/wp-content/uploads/2020/04/service-01.jpg

About UsAbout Lepton

Lepton Pharmaceuticals Inc. focuses on subtle and precise silencing/suppression of coding RNA expression by small non-coding RNA molecules working via the DROSHA/DICER/RISC pathways, small interfering RNA (siRNA), and microRNA (miRNA) to develop therapies for unmet medical needs
About Us
https://www.leptonpharma.com/wp-content/uploads/2020/06/large_blue_triangle_04.png
https://www.leptonpharma.com/wp-content/uploads/2020/03/blue_triangle_01.png

Our ProductsLepton’s proprietary breakthrough general platform to manipulate siRNAs & microRNAs

Our Pipeline
bt_bb_section_top_section_coverage_image

NewsLatest News

23 August 2023
Lepton Announced Completion of Filing for a Patent Application Extending the Usage of Its Castling Breakthrough Technologies
13 July 2023
Lepton Pharmaceuticals Completed the Extension Worldwide of its International Patent Covering the Breakthrough Castling Technology
20 March 2023
Lepton Pharmaceuticals enter into a Master Service Agreement with Reaction Biology to advance Lepton’s miRNA Castling Technology
https://www.leptonpharma.com/wp-content/uploads/2020/04/service_4.jpg
https://www.leptonpharma.com/wp-content/uploads/2021/04/logo_white_big-160x160.png

© 2023 Lepton Pharmaceuticals Inc.  All rights reserved
Design & Development by WCT

Our products

Our science

Terms of use